Loading…
← CockpitCompetitor Analysis › 000516.SZ Xi'an International Medical Investment Co. Ltd. Class AOpen in the cockpit ↗

Xi'an International Medical Investment Co. Ltd. Class A000516.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Hospital/Nursing Management

Xi'an-based hospital operator running general and specialty hospitals, part of a broader medical investment group.

≈ A Chinese regional hospital-group operatorMomentum leader 89
Mkt cap
$1.46B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$18.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.1 pp
WACC 7.4%
Hurdle
-8 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥4.39
1D-1.4%
1W-5.2%
1M+0.5%
3M+0.9%
6M-2.2%
YTD+2.3%
1Y-8.2%
ATR %2.6%
52w lowhigh29.1% off high

What Xi'an International Medical Investment does

Xi'an-based hospital operator running general and specialty hospitals, part of a broader medical investment group.

In one line: A Chinese regional hospital-group operator.

Products and services

  • General hospital services
  • Specialty hospital services

Customers

  • Patients in Xi'an/Shaanxi region

Where it sits in the supply chain

  • Health Care
  • Hospital/clinic services
  • General & specialty hospital operation

What could go right

  • Rising private healthcare demand in Shaanxi

What could go wrong

  • High capex/debt for hospital construction
  • Regional concentration

Moat: narrow (regulatory licence, scale). Regional hospital-operating licences and facility scale versus smaller clinics.

Headquarters: Xi'an, China · Employees: 8,055

Named competitors

Xi'an International Medical Investment at a glance

Size Xi'an International Medical Investment (000516.SZ) is a China Health Care company (Hospital/Nursing Management) with a market value of $1.46B, the 1549th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.39 on 18 Nov 2026.

Performance Over six months the shares fell 2.2%, against -6.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue fell 1.1% over the last twelve months (peer median +11.9%); the operating margin is -1.6% (peer median 10.0%).

Valuation It trades at 3.1× enterprise value to sales against a peer median of 2.6× (10th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.1 points below its cost of capital (7.4% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026000516.SZ 99Peer median 93
Six months, rebased to 100: Xi'an International Medical Investment against the median of its 20 peers (local-currency closes).

Xi'an International Medical Investment financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.16BCN¥4.07BCN¥4.82BCN¥4.55BCN¥2.71B
Revenue growth—-15%+6%+68%—
Gross profitCN¥943MCN¥167MCN¥278MCN¥156M-CN¥366M
EBITDAn/aCN¥415MCN¥545MCN¥454M-CN¥264M
Net income-CN¥89.8M-CN¥313M-CN¥254M-CN¥368M-CN¥1.18B
Free cash flowCN¥1.11BCN¥1.03BCN¥463MCN¥327M-CN¥703M
Capital expenditureCN¥207MCN¥262MCN¥548MCN¥763MCN¥1.19B
Total debtCN¥3.94BCN¥4.21BCN¥4.64BCN¥4.74BCN¥4.46B

Quarterly statements and history in the cockpit →

Xi'an International Medical Investment competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-10%0%+10%+20%AEVSRAINBOW301293SIASPICVSG301267YATHARTHEXEPARKHOSPSRHKARDTBKDJLHLCBAVGDSA50000516.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Xi'an International Medical Investment is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%2×4×6×AEVSRAINBOW301293SIASPIBSLCVSG301267YATHARTHEXEPARKHOSPSRHKARDTBKDJLHLCBAVGDSPARASHLTHHCGA50000516.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xi'an International Medical Investment is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%AEVSRAINBOWSIASPIBSLCVSG301267EXEPARKHOSPSARDTBKDCBAVGDS000516.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Xi'an International Medical Investment is the large dot.

Xi'an International Medical Investment competitors and peer comparison

Head to head with its named competitors (000516.SZ vs 600763.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Xi'an International Medical Investment 000516.SZ$1.46B-2%-1%-2%3.1×12.7%
Topchoice Medical 600763.SS$2.33B-12%+7%26%5.3×12.4%

How Xi'an International Medical Investment compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xi'an International Medical Investment against its 20 peers (data as of 18 Nov 2026)
Measure000516.SZPeer medianRank in peer set
1-month return+0.5%+1.6%8th lowest of 20
6-month return-2.2%-6.9%9th highest of 20
Distance from 52-week high-29.1%-21.9%6th lowest of 21
Revenue growth (TTM)-1.1%+11.9%3rd lowest of 21
Operating margin-1.6%10.0%3rd lowest of 21
EV / Sales3.1×2.6×10th most expensive of 21
Growth the price implies (Req g, 7 yrs)12.7%12.5%8th least demanding of 15
Growth delivered (Del g)+20.6%+9.5%2nd highest of 15
Hurdle (Req g minus delivered)-7.9 pp+4.8 pp5th least demanding of 15
ROIC minus cost of capital-2.1 pp-2.7 pp10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xi'an International Medical Investment 000516.SZChina$1.46B-2%-1%-2%3.1×12.7%+20.6%
Aevis Victoria AEVS.SWSwitzerland$1.43B+8%+15%-6%1.8×26.5%+10.2%
Rainbow Childrens Medicare RAINBOW.NSIndia$1.37B-7%+23%22%7.0×30.7%+21.2%
Sanbo Hospital Management 301293.SZChina$1.35B-29%+17%6%4.9×n/an/a
Sienna Senior Living SIA.TOCanada$1.58B-8%+15%10%3.1×18.9%+8.6%
Spire Healthcare SPI.LUnited Kingdom$1.31B+11%+2%8%1.4×10.0%+11.4%
Raffles Medical BSL.SISingapore$1.23B-13%-3%11%1.8×-2.7%+6.1%
CVS CVSG.LUnited Kingdom$1.22B+17%+6%11%1.7×14.2%+6.9%
Huaxia Eye Hospital 301267.SZChina$1.78B-18%+2%15%2.1×2.1%+10.4%
Yatharth Hospital and Trauma Care Services YATHARTH.NSIndia$1.13B+31%+50%16%7.2×n/an/a
Extendicare EXE.TOCanada$1.91B-16%+36%9%1.5×10.8%+8.5%
Park Medi World PARKHOSPS.NSIndia$1.10B-4%+21%21%5.8×22.1%+10.2%
Rhon-klinikum RHK.DEGermany$1.06B+15%+4%-51%0.6×n/an/a
Ardent Health ARDTUnited States$2.03B+52%+2%5%0.6×-1.7%+8.7%
Brookdale Senior Living BKDUnited States$2.06B-36%-8%6%2.4×19.3%-1.4%
Jupiter Life Line Hospitals JLHL.NSIndia$1.01B+9%+17%16%6.0×n/an/a
Clinica Baviera CBAV.MCSpain$1.01B+2%+11%20%2.8×2.3%+19.7%
Ramsay Generale de Sante GDS.PAFrance$969M-25%+3%4%0.9×6.1%+6.0%
Paras Healthcare PARASHLTH.NSIndia$962Mn/a+24%11%6.4×n/an/a
HealthCare Global Enterprises HCG.NSIndia$955M-7%+13%8%3.9×n/an/a
Thomson Medical A50.SISingapore$923M-18%+6%10%5.5×21.2%+11.8%

Questions

Who are Xi'an International Medical Investment's main competitors?
Named competitors: Topchoice Medical (600763.SS). The cockpit's measured peer set (industry) also includes Aevis Victoria (AEVS.SW), Rainbow Childrens Medicare (RAINBOW.NS), Sanbo Hospital Management (301293.SZ), Sienna Senior Living (SIA.TO), Spire Healthcare (SPI.L), Raffles Medical (BSL.SI).
Is Xi'an International Medical Investment expensive compared with its peers?
On ev / sales it trades at 3.1× against a peer median of 2.6×, 10th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Xi'an International Medical Investment stock performed?
Over six months to 18 Nov 2026 the shares returned -2.2% against -6.9% for the median peer; over one year -8.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.